A phase II study of capecitabine [Xeloda] and oxaliplatin [Eloxatin; Xelox] in adenocarcinoma of the small bowel and ampulla of Vater.

Trial Profile

A phase II study of capecitabine [Xeloda] and oxaliplatin [Eloxatin; Xelox] in adenocarcinoma of the small bowel and ampulla of Vater.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2012

At a glance

  • Drugs Capecitabine; Oxaliplatin
  • Indications Biliary cancer; Intestinal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jan 2010 Actual patient numbers amended from 30 to 31 as reported by ClinicalTrials.gov.
    • 05 Jan 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Final results were published in the Journal of Clinical Oncology in Jan 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top